Real-World Study: Mounjaro Outshines Ozempic in Weight Loss

In a groundbreaking real-world study, Eli Lilly's Mounjaro (tirzepatide) demonstrated superior weight loss compared to Novo Nordisk's Ozempic (semaglutide), both of which are popular drugs for treating type 2 diabetes and obesity. This study, published in JAMA Internal Medicine, marks the first head-to-head comparison of these two drugs using healthcare data from everyday clinical settings. The findings reveal that patients taking Mounjaro not only hit weight-loss benchmarks more consistently but also lost more weight overall compared to those taking Ozempic.

Mounjaro and Ozempic belong to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs work by mimicking natural hormones in the gut and brain that regulate blood sugar levels and appetite.

Previous clinical trials have shown that patients on Ozempic can lose up to 16% of their total body weight. Mounjaro, however, has delivered even more impressive results, with some patients shedding more than 20% of their body weight. Although these results from clinical trials were promising, they couldn't be directly compared due to differences in how the trials were conducted. This new real-world study, however, provides a direct comparison and suggests that Mounjaro is indeed more effective for weight loss.

The study found that over a one-year period, patients on Mounjaro were three times as likely to achieve a weight loss of 15% or more compared to those on Ozempic. The total weight loss was consistently greater for Mounjaro users across various intervals—three, six, and twelve months—with the difference between the two drugs widening over time. For instance, at three months, the average weight loss for Mounjaro was 5.9%, compared to Ozempic's 3.6%. By the one-year mark, Mounjaro patients had lost over 15% of their body weight, while Ozempic users had lost about 8%.

The study also examined the safety profiles of both drugs. GLP-1 drugs are known for their gastrointestinal side effects, including nausea, diarrhea, and vomiting. More severe complications like bowel obstruction, gastroparesis, and pancreatitis have also been reported. However, the study found no significant difference in the rates of moderate to severe gastrointestinal adverse events between Mounjaro and Ozempic.

This real-world study offers valuable insights into the effectiveness of Mounjaro and Ozempic for weight loss, especially in patients struggling with obesity. While both drugs are effective, Mounjaro appears to be the stronger option for those aiming to achieve significant weight loss. As the use of these drugs continues to evolve, ongoing research will be crucial in understanding their long-term impacts and optimising their use in clinical practice.